Pens' Nasreddine waits to learn status
Alain Nasreddine will know right before faceoff tonight whether he will play against New Jersey. Defensemen Brooks Orpik (mild concussion) and Darryl Sydor (groin), both of whom sat out Monday's practice, returned to the ice yesterday and showed no ill effects of their injuries.
"It's feeling good and we'll see if it gets tight or anything like that, but I'm expecting to play," Sydor said. "I felt pretty good out there and I was quite surprised that I didn't really feel it too much, but whenever you do have a strain, it's always good to take precautions."
Orpik absorbed a blow to the head by Toronto left wing Simon Gamache in Saturday's 6-4 win over the Maple Leafs but isn't suffering from headaches or nausea. Whether he will play will be a decision made by coach Michel Therrien and not the training staff, which deems him medically cleared to play.
While Orpik and Sydor may dot the lineup tonight it may take a little longer for forward Georges Laraque to reclaim his spot on the fourth line.
Laraque (groin) was kept out of the team's regular workout for the second straight day and, though he did take the ice briefly with strength and conditioning coach Mike Kadar before practice, he stayed out for only a few minutes and was not in full pads.
9 - Consecutive road games New Jersey will play to start the season while the Prudential Center in Newark is completed.
48 - Evgeni Malkin's rank (tied with 33 others) among the NHL's scoring leaders, the highest of any Penguins player.
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.
- Penguins score 1st win in San Jose in 18 years
- Pitt’s surge goes for naught as No. 11 Purdue prevails at Pete
- Pirates showing interest in starting pitcher Masterson
- Steelers notebook: Opportunity awaits Boykin
- Boras: Alvarez’s power is too valuable for Pirates to let him leave
- Web-savvy terrorists have success luring U.S. recruits with social media
- Stylish, inexpensive dress takes television newsrooms by storm
- Overseas data, financial shares lead stocks to strong December start
- Greater Latrobe doesn’t intend to raise taxes above index set by state
- Perryopolis, Perry Township communities talk ambulance woes
- Express Scripts to offer alternative to $750 toxoplasmosis medication